Xstim, Inc. receives FDA approval for Xstim™ Spine Fusion Stimulator

Xstim, Inc. announced Premarket Application (PMA) approval from the U.S. Food and Drug Administration (FDA) for Xstim™ Spine Fusion Stimulator. Engineered with patient comfort and convenience in mind, the Xstim™ Spine Fusion Stimulator represents a significant milestone in the company’s product lineup of bone growth stimulators. This capacitively coupled device emits a low-energy signal clinically proven to promote bone healing after spinal fusion surgery. Commercial availability of the Xstim device is slated for the second quarter of this year, with a targeted and phased launch plan in place to ensure widespread accessibility.

The Xstim device has been meticulously designed to prioritize patient ease of use and wearability, offering a noninvasive alternative for indicated cases. With its intuitive interface and sleek design, featuring a large onboard color display, the Xstim device streamlines patient therapy management.

Dr. Adam Bruggerman, MD, commented on the significance of Xstim, stating, “Bone healing following spinal fusion surgery is paramount to successful patient outcomes. The availability of non-invasive bone growth stimulation options like Xstim provides my patients with an invaluable advantage. Its sleek design ensures simple therapy management without the hassle of downloading and managing extra apps.”

Jeremy Perkins, Chief Executive Officer of Xstim, Inc., expressed the company’s commitment to enhancing spinal fusion rehabilitation standards, saying, “Xstim, Inc. is dedicated to empowering patients and surgeons to elevate the quality of care in spinal fusion rehabilitation. The introduction of the Xstim Spine Fusion Stimulator represents the beginning of our robust pipeline of bone growth stimulation innovations. We are poised to collaborate with healthcare providers and distribution partners to enhance bone fusion outcomes and elevate patient satisfaction. This FDA approval underscores our leadership in and dedication to the bone growth stimulation market.”
MB Bureau